<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00007891</url>
  </required_header>
  <id_info>
    <org_study_id>CRICC-BB-IND-7186</org_study_id>
    <secondary_id>CDR0000068340</secondary_id>
    <secondary_id>UCHSC-97467</secondary_id>
    <secondary_id>NCI-V00-1637</secondary_id>
    <nct_id>NCT00007891</nct_id>
  </id_info>
  <brief_title>Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase I Study of 90-Y-Humanized-BrE-3 Followed by Autologous Hematopoietic Progenitor Cell Support in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research Institute of Contra Costa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or&#xD;
      deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell&#xD;
      transplantation or bone marrow transplantation may be able to replace immune cells that were&#xD;
      destroyed by monoclonal antibody therapy used to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy&#xD;
      followed by bone marrow or peripheral stem cell transplantation in treating patients who have&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of yttrium Y 90 labeled, humanized monoclonal&#xD;
           antibody BrE-3 when given in combination with indium In 111 labeled, humanized&#xD;
           monoclonal antibody BrE-3 followed by autologous bone marrow or peripheral blood stem&#xD;
           cell transplantation in patients with metastatic breast cancer.&#xD;
&#xD;
        -  Determine hematopoietic engraftment in these patients treated with this regimen.&#xD;
&#xD;
        -  Determine the ability of indium In 111 labeled, humanized monoclonal antibody BrE-3 to&#xD;
           image metastatic disease in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the preliminary antitumor response in these patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of yttrium Y 90 labeled, humanized monoclonal&#xD;
      antibody BrE-3 (Y90 huMOAB BrE-3).&#xD;
&#xD;
      Patients receive Y90 huMOAB BrE-3 and indium In 111 labeled, humanized monoclonal antibody&#xD;
      BrE-3 IV over 1-2 hours on day -14. Patients undergo autologous bone marrow or peripheral&#xD;
      blood stem cell transplantation on day 0. Patients also receive filgrastim (G-CSF) IV&#xD;
      beginning on day 0 and continuing until blood counts recover.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of Y90 huMOAB BrE-3 until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicities.&#xD;
&#xD;
      Patients are followed every 3-4 months for 1 year and then at least annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>indium In 111 monoclonal antibody BrE-3</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 monoclonal antibody BrE-3</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic breast cancer&#xD;
&#xD;
               -  BrE-3 positive&#xD;
&#xD;
               -  Relapsed or refractory disease with tumor progression after effective therapy&#xD;
                  allowed&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Received at least one prior chemotherapy regimen for metastatic disease and have at&#xD;
             least one of the following:&#xD;
&#xD;
               -  Chemotherapy refractory liver metastases more than 2 cm&#xD;
&#xD;
               -  Multiple non-resectable liver metastases&#xD;
&#xD;
               -  Brain metastases&#xD;
&#xD;
               -  Prior high-dose chemotherapy&#xD;
&#xD;
               -  Relapse within prior radiotherapy field&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,000/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2 times normal&#xD;
&#xD;
          -  SGOT/SGPT less than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  LVEF greater than 45% by MUGA scan&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO and FEV 1.0 greater than 60% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known hypersensitivity to E. coli derived proteins&#xD;
&#xD;
          -  No other comorbid condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior high-dose chemotherapy with autologous peripheral blood stem cell&#xD;
             transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto L. Ceriani, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research Institute of Contra Costa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Research Institute of Contra Costa</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2004</verification_date>
  <study_first_submitted>January 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

